Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DNAtrix's platforms leverage the unique characteristics of oncolytic viruses to develop a pipeline of safe and effective therapies for hard to treat cancers that have shown resistance to conventional therapies. Our platform of clinical stage oncolytic adenoviruses include DNX-2401 (tasadenoturev) and DNX-2440. These viruses have demonstrated the ability to selectively kill tumor cells and trigger long term antitumor immunity....
DNAtrix's platforms leverage the unique characteristics of oncolytic viruses to develop a pipeline of safe and effective therapies for hard to treat cancers that have shown resistance to conventional therapies. Our platform of clinical stage oncolytic adenoviruses include DNX-2401 (tasadenoturev) and DNX-2440. These viruses have demonstrated the ability to selectively kill tumor cells and trigger long term antitumor immunity. DNAtrix is continuing to expand its pipeline by developing viruses armed with a variety of potent immunomodulatory molecules designed to unleash robust immune responses against tumors.

List your booth number for exhibitions, ask us